NCT03299166

Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive Disorder

A Randomized, Double-blind, Placebo-controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 426 (actual)
• Sponsor: Biohaven Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy of troriluzole as adjunctive therapy versus placebo in participants with obsessive compulsive disorder (OCD) who had an inadequate response to selective serotonin reuptake inhibitor (SSRI), clomipramine, venlafaxine, or desvenlafaxine treatment

Conditions

• Obsessive-Compulsive Disorder

Interventions

Type	Name	Description
DRUG	Troriluzole	Troriluzole, 140 mg capsules once daily (QD) orally for the first 4 weeks and 200 mg (140 mg+ 60 mg capsules QD) for an additional 8 weeks
DRUG	Placebo	Matching capsule once daily (QD)

Timeline

• Start date: 2017-12-19
• Primary completion: 2020-06-02
• Completion: 2025-12-08
• First posted: 2017-10-02
• Last updated: 2026-01-22
• Results posted: 2023-06-02

Locations

57 sites across 1 country: United States

Regulatory

• FDA-regulated drug study